Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA – Get Free Report)’s stock price rose 2.3% during trading on Monday . The company traded as high as $3.43 and last traded at $3.15. Approximately 86,496 shares traded hands during mid-day trading, a decline of 33% from the average daily volume of 129,011 shares. The stock had previously closed at $3.08.
Hepion Pharmaceuticals Price Performance
The company has a market capitalization of $12.09 million, a PE ratio of -0.27 and a beta of 1.77. The business has a 50-day moving average of $4.43 and a 200 day moving average of $7.70.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. BlackRock Inc. increased its holdings in Hepion Pharmaceuticals by 0.3% during the 1st quarter. BlackRock Inc. now owns 1,602,772 shares of the company’s stock worth $1,245,000 after purchasing an additional 5,206 shares during the period. Renaissance Technologies LLC increased its holdings in Hepion Pharmaceuticals by 5.8% during the 4th quarter. Renaissance Technologies LLC now owns 245,600 shares of the company’s stock worth $74,000 after purchasing an additional 13,500 shares during the period. State Street Corp increased its holdings in Hepion Pharmaceuticals by 8.1% during the 1st quarter. State Street Corp now owns 348,910 shares of the company’s stock worth $450,000 after purchasing an additional 26,194 shares during the period. Envestnet Asset Management Inc. increased its holdings in Hepion Pharmaceuticals by 45.8% during the 3rd quarter. Envestnet Asset Management Inc. now owns 87,541 shares of the company’s stock worth $44,000 after purchasing an additional 27,487 shares during the period. Finally, Virtu Financial LLC increased its holdings in shares of Hepion Pharmaceuticals by 152.8% in the 1st quarter. Virtu Financial LLC now owns 53,501 shares of the company’s stock valued at $42,000 after acquiring an additional 32,336 shares during the period. Institutional investors own 13.50% of the company’s stock.
About Hepion Pharmaceuticals
Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.
- Five stocks we like better than Hepion Pharmaceuticals
- Mega Cap Stocks: What They Are and How to Invest
- The most upgraded stocks in November have two things in common
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Monday.com rocked earnings like it’s the weekend
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Plan to own one retailer? Make it this one
Receive News & Ratings for Hepion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hepion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.